



Repligen Corporation
41 Seyon Street
Building #1, Suite 100
Waltham, Massachusetts 02453
Telephone: 781-250-0111
Telefax: 781-250-0115

FOR IMMEDIATE RELEASE

CONTACT:

Walter C. Herlihy, Ph.D.
President and Chief Executive Officer
(781) 419-1900

Laura L. Whitehouse
Vice President, Market Development
(781) 419-1812

Repligen First in North America to Receive Certification for Business Continuity

WALTHAM, MA – July 8, 2008 – Repligen Corporation (NASDAQ: RGEN) announced today that it is the first company in North America to receive certification to BS25999, the new standard for business continuity management. Business continuity management systems are designed to build resiliency within an organization and to ensure continued operations in the event of a business disruption, whether due to a major disaster or a minor incident. Repligen developed and implemented a business continuity management system to ensure an uninterrupted supply of its recombinant Protein A products, a key consumable used by the biopharmaceutical industry to manufacture drugs called monoclonal antibodies. Certification of Repligen’s business continuity management system to BS25999 demonstrates that our program meets globally accepted best practices for business continuity.

“As the world’s leading supplier of recombinant Protein A, we felt that it was important to be on the cutting edge of business continuity to ensure an uninterrupted supply of products to our customers and ultimately to patients,” stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. “We are very proud to be the first company in North America to have gained certification.”

Although Repligen has had a corporate commitment to business continuity and business continuity planning for several years, certification to BS25999 has only been available since November 2007. Repligen’s certification was granted by BSI Management Systems, the world’s leading quality management systems registrar.

Repligen is the world’s leading supplier of recombinant Protein A, a consumable used in the manufacture of therapeutic monoclonal antibodies. There are approximately 20 monoclonal antibodies that have received regulatory approval with more than 200 products in various stages of clinical development. The worldwide revenues from this class of drug were approximately \$30 billion in 2007. Monoclonal antibodies are the largest and fastest growing class of drug in the biopharmaceutical industry.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world’s leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are

located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from www.repligen.com.

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.